Author: Terhune Julia Berk Erik Czerniecki Brian J.
Publisher: MDPI
E-ISSN: 2076-393x|1|4|527-549
ISSN: 2076-393x
Source: Vaccines, Vol.1, Iss.4, 2013-11, pp. : 527-549
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The success of cellular immunotherapies against cancer requires the generation of activated CD4+ and CD8+ T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a type-1 response is needed for optimal cancer treatment. IL-17 producing T-cells (Th17/Tc17) play an important role in autoimmune diseases, but their function in cancer is more controversial. While some studies have shown a pro-cancerous role for IL-17, other studies have shown an anti-tumor function. The induction of polarized T-cell responses can be regulated by dendritic cells (DCs). DCs are key regulators of the immune system with the ability to affect both innate and adaptive immune responses. These properties have led many researchers to study the use of
Related content
By Elshal Mohamed F. Aldahlawi Alia M. Saadah Omar I. McCoy J. Philip
International Journal of Molecular Sciences, Vol. 16, Iss. 12, 2015-12 ,pp. :
Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
By Koido Shigeo
International Journal of Molecular Sciences, Vol. 17, Iss. 6, 2016-05 ,pp. :